ABC | Volume 110, Nº4, April 2018

Original Article Muñoz et al Atrial fibrillation ablation in valve disease Arq Bras Cardiol. 2018; 110(4):312-320 This is an open-access article distributed under the terms of the Creative Commons Attribution License 21. SchopkaS,SchmidC,KeyserA,KortnerA,Tafelmeier J,DiezC,etal.Ablation of atrial fibrillationwith the Epicor system: a prospective observational trial to evaluate safety and efficacy and predictors of success. J Cardiothorac Surg. 2010 May 5;5:34. doi: 10.1186/1749-8090-5-34. 22. Kourliouros A, Savelieva I, Kiotsekoglou A, Jahangiri M, Camm J. Current concepts in the pathogenesis of atrial fibrillation. Am Heart J. 2009;157(2):243-52. doi: 10.1016/j.ahj.2008.10.009. 23. Nakashima H, Kumagai K, Urata H, Gondo N, Ideishi M, Arakawa K. Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation. Circulation. 2000;101(22):2612-7. doi: https://doi.org/10.1161/01. CIR.101.22.2612. 24. Tayebjee MH, Creta A, Moder S, Hunter RJ, Earley MJ, Dhinoja MB, et al. Impactofangiotensin-convertingenzyme-inhibitorsandangiotensinreceptor blockers on long-term outcome of catheter ablation for atrial fibrillation. Europace. 2010;12(11):1537-42. doi: 10.1093/europace/euq284. 25. AdN, Suri RM, Gammie JS, Sheng S, O’Brien SM, Henry L. Surgical ablation of atrial fibrillation trends and outcomes in North America. J Thorac Cardiovasc Surg. 2012;144(5):1051-60. doi: 10.1016/j.jtcvs.2012.07.065. 320